Agate Pass Investment Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-7,984
Closed -$293K 112
2026
Q1
$293K Sell
7,984
-260
-3% -$12.3K 0.11% 92
2025
Q4
$419K Sell
8,244
-575
-7% -$29.4K 0.16% 93
2025
Q3
$489K Buy
8,819
+550
+7% +$32.2K 0.19% 85
2025
Q2
$571K Buy
8,269
+650
+9% +$44.2K 0.23% 80
2025
Q1
$529K Sell
7,619
-400
-5% -$33K 0.23% 84
2024
Q4
$690K Sell
8,019
-4,731
-37% -$512K 0.31% 78
2024
Q3
$1.52M Sell
12,750
-475
-4% -$63.3K 0.76% 41
2024
Q2
$1.89M Sell
13,225
-597
-4% -$79.1K 1% 33
2024
Q1
$1.77M Sell
13,822
-549
-4% -$65.4K 0.95% 34
2023
Q4
$1.49M Buy
14,371
+425
+3% +$42K 0.86% 37
2023
Q3
$1.27M Sell
13,946
-710
-5% -$62.5K 0.86% 37
2023
Q2
$1.19M Sell
14,656
-470
-3% -$38.4K 0.72% 41
2023
Q1
$1.2M Sell
15,126
-250
-2% -$17.7K 0.79% 41
2022
Q4
$1.04M Buy
15,376
+40
+0.3% +$2.35K 0.74% 42
2022
Q3
$764K Sell
15,336
-360
-2% -$19.3K 0.58% 47
2022
Q2
$875K Buy
15,696
+60
+0.4% +$3.33K 0.62% 47
2022
Q1
$868K Buy
15,636
+900
+6% +$46.2K 0.54% 52
2021
Q4
$825K Buy
+14,736
New +$798K 0.51% 54

Other funds holding NVO

Agate Pass Investment Management's NVO Position: Q2 2026 in Review

Agate Pass Investment Management sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 7,984 shares — an estimated $293K sold.

Agate Pass Investment Management first reported a position in NVO in Q4 2021 and held it in 18 quarters. The position peaked at $1.89M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Agate Pass Investment Management reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • Agate Pass Investment Management sold 7,984 Novo Nordisk shares in Q2 2026, an estimated $293K.
  • Agate Pass Investment Management first reported a position in Novo Nordisk in Q4 2021 and held it in 18 quarters.
  • Agate Pass Investment Management's Novo Nordisk position peaked at $1.89M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Agate Pass Investment Management's 13F filing for Q2 2026, filed 8 Jul 2026.